AZ, ISIS expand partnership to develop novel delivery methods for antisense oligonucleotides
Isis Pharmaceuticals and AstraZeneca have expanded their partnership to develop novel delivery methods for antisense oligonucleotides in order to target the desired tissue more effectively.